Found 1437 Enz. Inhib. hit(s) with Target = 'Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327]'
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 0.900nM ΔG°: -51.5kJ/mole IC50: 3.40nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.20nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.70nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.60nM ΔG°: -50.0kJ/mole IC50: 5.96nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 16nM ΔG°: -44.3kJ/mole IC50: 59.5nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 44nM ΔG°: -41.8kJ/mole IC50: 162nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 64nM ΔG°: -40.9kJ/mole IC50: 237nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 104nM ΔG°: -39.7kJ/mole IC50: 383nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0160nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0160nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0180nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0180nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0190nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0200nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0220nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0240nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0240nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0250nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0260nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0260nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0260nMAssay Description:The inhibition of the Mcl-1/Bim interaction was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The recombinan...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0270nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0290nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0290nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0290nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0290nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0290nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0300nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0300nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0300nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0300nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0300nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The inhibition of the Mcl-1/Bim interaction was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The recombinan...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0310nMAssay Description:The inhibition of the Mcl-1/Bim interaction was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The recombinan...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0320nMAssay Description:The inhibition of the Mcl-1/Bim interaction was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The recombinan...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0320nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0320nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0330nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0330nMAssay Description:The inhibition of the Mcl-1/Bim interaction was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The recombinan...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0330nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0330nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0330nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0340nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0350nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataIC50: 0.0350nMAssay Description:The AlphaLISA assay was performed in a 384-well Proxiplate in a total volume of 40 μL. The reaction mixture contained 0.0625 nM 6× His-Mcl-1 (17...More data for this Ligand-Target Pair